Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Wendy Wright

Nurse Practitioner, Family Amherst, NH Nurse Practitioner

NPI 1346274941 CMS profile 10825041

282 State Route 101 Unit 9, Amherst, NH 03031

Open in the dashboard

General payments

$447,263

793 records reported · program years 2021–2025

Research payments

$6,400

Paid to them · 2 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wendy Wright of Amherst, NH is reported in the CMS Open Payments database as having received $447,263 across 793 general payments and $6,400 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $142,286 235
2024 General $110,047 189
2023 General $78,787 152
2022 General $69,666 132
2022 Research $3,200 1
2021 General $46,477 85
2021 Research $3,200 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wendy Wright
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Wendy Wright were reported at $142,286. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Wendy Wright Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $46,477 $124 $35–$379 $132
2022 $69,666 $141 $44–$430 $149
2023 $78,787 $154 $49–$476 $160
2024 $110,047 $165 $51–$504 $164
2025 $142,286 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $96,447 150 payments
  2. Pfizer Inc. $73,948 60 payments
  3. Exact Sciences Corporation $56,406 128 payments
  4. Idorsia Pharmaceuticals US Inc $41,039 97 payments
  5. AbbVie, Inc. $24,625 108 payments
  6. Axsome Therapeutics, Inc. $19,853 29 payments
  7. Biohaven Pharmaceuticals, Inc. $18,884 39 payments
  8. Seqirus USA Inc $18,831 20 payments
  9. Sanofi Pasteur Inc. $17,103 27 payments
  10. Merck Sharp & Dohme Corporation $16,964 25 payments
  11. Other $63,165 110 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $218,166 153 payments
  2. Consulting Fee $128,162 100 payments
  3. Travel and Lodging $61,813 232 payments
  4. Honoraria $25,725 13 payments
  5. Food and Beverage $13,333 293 payments
  6. Education $65 2 payments
Products named General payments · program years 2021–2025
  1. Cologuard Collection Kit $47,782 103 payments
  2. AIRSUPRA $45,844 72 payments
  3. QUVIVIQ $41,039 97 payments
  4. BREZTRI $30,187 48 payments
  5. COMIRNATY $26,634 21 payments
  6. NURTEC ODT $22,532 45 payments
  7. TRUMENBA $17,415 7 payments
  8. ABRYSVO $15,025 14 payments
  9. UBRELVY $12,637 44 payments
  10. Auvelity $11,564 13 payments
  11. Other $84,731 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Pfizer Inc. $6,400 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

708

Median for Nurse Practitioner: 389

Drug cost

$32,765

Median for Nurse Practitioner: $21,885

Branded share of claims

15.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 16 $16,386
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 34 $10,249
Tamsulosin Hcl Generic 24 $598
Venlafaxine Hcl Er Venlafaxine Hcl Brand 12 $564
Atorvastatin Calcium Generic 84 $551
Losartan Potassium Generic 65 $449
Levothyroxine Sodium Generic 57 $413
Duloxetine Hcl Generic 19 $396
Pantoprazole Sodium Generic 27 $394
Rosuvastatin Calcium Generic 70 $388

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$48,008

Of which drugs: $10,585

Medicare patients

117

Average age 72

Services billed

1,004

87 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Depression 41%
Arthritis 38%
Diabetes 21%
Osteoporosis 21%
Chronic kidney disease 18%
COPD 16%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 39 45 $6,486
Vaccine for influenza for injection into muscle 90662 Office 31 31 $2,536

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$22,523 — —
ABRYSVO
$10,412 — —
BREZTRI
$6,868 — —
ZAVZPRET
$6,400 — —
MENQUADFI
$972 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

795 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record